-
A GENERATIVE AI SUITE FOR REAL-WORLD EVIDENCE STUDY DOCUMENTATION: MULTI-MODULE VALIDATION ACROSS PHARMACOEPIDEMIOLOGICAL DELIVERABLES
Aug 11, 2026, 17:15 PM -
THE IMPACT OF NATIONAL PHARMACEUTICAL SPENDING CAPS ON FIRMS' R&D INVESTMENT DECISIONS: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:15 PM -
MODELING FUTURE EPIDEMIOLOGICAL AND ECONOMIC BURDEN OF HIV IN BRAZIL: PROJECTION OF SUBSTANTIAL NEW INFECTIONS AND COSTS THROUGH TO 2034
Aug 11, 2026, 17:15 PM -
MENTAL HEALTH HEOR EVIDENCE GENERATION AND GROWTH OF REAL-WORLD EVIDENCE AMID INCREASING DISEASE BURDEN: AN AI-ASSISTED LONGITUDINAL ANALYSIS, 2014-2023
Aug 11, 2026, 17:15 PM -
HAS FRANCE'S EARLY ACCESS SCHEME BECOME MORE SELECTIVE? EVIDENCE FROM TEMPORAL TRENDS IN EARLY ACCESS AND SUBSEQUENT ASMR RATINGS
Aug 11, 2026, 17:15 PM -
RETURN ON INVESTMENT OF ONE-TIME LIPOPROTEIN(A) TESTING FOR CARDIOVASCULAR RISK PREVENTION IN BULGARIA
Aug 11, 2026, 17:15 PM -
TARGETED LITERATURE REVIEW TO DEVELOP DISEASE CONCEPTUAL MODEL OF IGG4-RD
Aug 11, 2026, 17:15 PM -
A HARMONIZED APPROACH TO MENTAL HEALTH REFERENCE UNIT COST DEVELOPMENT USING PROVIDER-REPORTED PRIMARY DATA: EVIDENCE FROM THE STREAMLINE PROJECT
Aug 11, 2026, 17:15 PM -
WHY ASSESSORS ASK: ANTICIPATING AND MANAGING INFORMATION REQUESTS IN THE FIRST WAVE OF JCAS
Aug 11, 2026, 17:15 PM -
A NARRATIVE REVIEW AND PATIENT-REPORTED OUTCOME (PRO) LANDSCAPE ASSESSMENT TO INFORM THE DEVELOPMENT OF THE NOVEL SUICIDAL AND SELF-INJURIOUS BEHAVIOR SCALE (SASIBS)
Aug 11, 2026, 17:15 PM -
HOW NATIONAL HTA SYSTEMS ARE BEING RESHAPED IN RESPONSE TO EU HTA: A REVIEW OF CURRENT REFORMS AND EARLY IMPLEMENTATION
Aug 11, 2026, 17:15 PM -
BUDGET IMPACT ANALYSIS OF SOUVENAID FOR THE MANAGEMENT OF ALZHEIMER'S DISEASE IN MIDDLE EAST AND NORTH AFRICA REGION
Aug 11, 2026, 17:15 PM -
HOW HAVE PRICES ACROSS THERAPY AREAS AND COUNTRIES EVOLVED OVER THE LAST 5 YEARS AND WHAT IMPACT CAN WE EXPECT PRICE REFERENCING POLICIES SUCH AS MFN TO HAVE IN THE FUTURE?
Aug 11, 2026, 17:15 PM -
LONG-TERM REAL-WORLD PATIENT-REPORTED OUTCOMES AND URGENCY ON ADALIMUMAB IN ULCERATIVE COLITIS: 36-MONTH TRAJECTORIES FROM THE AMPERSAND DIGITAL COHORT
Aug 11, 2026, 17:15 PM -
ASSOCIATION BETWEEN VASOMOTOR SYMPTOM RESPONSE AND EQ-5D IN WOMEN WITH BREAST CANCER EXPERIENCING MODERATE-TO-SEVERE VASOMOTOR SYMPTOMS CAUSED BY ADJUVANT ENDOCRINE THERAPY
Aug 11, 2026, 17:15 PM -
CLINICAL UTILITY OF ENHANCED LIVER FIBROSIS (ELF)-GUIDED REFERRAL STRATEGIES: A DECISION CURVE ANALYSIS IN US VETERANS
Aug 11, 2026, 17:15 PM -
CURRENT TREATMENT PATTERNS IN NON-METASTATIC MELANOMA IN THE MODERN TREATMENT ERA: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)-MEDICARE ANALYSIS
Aug 11, 2026, 17:15 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH NON-SURGICAL AND POST-SURGICAL HYPOPARATHYROIDISM: A REAL-WORLD CLAIMS ANALYSIS
Aug 11, 2026, 17:15 PM -
COST-UTILITY ANALYSIS FROM VARYING RATES OF SCREENING AND FOLLOW-UP COLONOSCOPY: REAL-WORLD ANALYSIS OF TAIWAN COLORECTAL CANCER SCREENING PROGRAM
Aug 11, 2026, 17:15 PM -
THE HIDDEN ECONOMIC AND HEALTHCARE BURDEN OF NAMD IN THE USA AND GERMANY EVIDENCE FROM A 20-YEAR SOCIAL IMPACT MODEL
Aug 11, 2026, 17:15 PM
